More than 7% of the US population who have diabetes are at a 2 to 6-fold higher risk for having ischemic stroke and suffer from unfavorable stroke outcome and poor recovery. Reperfusion therapy with tissue plasminogen activator (tPA) is the only therapy for ischemic stroke; however, this treatment increases the risk of bleeding into the brain (hemorrhagic transformation, HT), especially in diabetics. A critical barrier to progress in the development of new therapeutic strategies, as well as the proper use of tPA in high-risk populations, is the lack of understanding on how bleeding influences the repair and recovery after stroke. Our goal is to identify new targets for prevention and treatment of stroke i patients with preexisting vascular disease and develop new neurovascular protection strategies. Our objective is to address this critical barrier and clinical problem by defining the impact and mechanisms by which HT impairs neurovascular repair after ischemic stroke in diabetes. Our central hypothesis is that bleeding into the brain, petechial OR space- occupying, impairs neurovascular restoration and worsens outcome in diabetes via the activation of toll like receptor (TLR)-4 by excess iron, a novel damage associated molecular pattern (DAMP). This hypothesis will be tested in 3 Specific Aims: 1. Test the hypothesis that petechial nonspace-occupying HT impairs neurovascular restorative repair and worsens neurological deficits in diabetes. We will determine the extent to which HT impairs neurovascular repair and functional outcome in multiple models of stroke and diabetes; 2. Test the hypothesis that iron deposition resulting from greater HT in diabetes impairs neurovascular plasticity and worsens outcome of ischemic stroke. We will determine the role of iron on neurovascular restoration and functional outcome after embolic stroke in Type 2 diabetes; and 3. Test the hypothesis that HT stimulates TLR4 signaling/inflammation worsening repair and recovery after diabetic ischemic stroke. We will determine the mechanisms by which HT impairs functional recovery after embolic stroke in Type 2 diabetes. The outcomes of our translational studies include: 1) demonstrating that any bleeding into the brain is detrimental by impairing vascular and neuronal repair (this challenges the existing paradigm that only space-occupying HT worsens outcomes); 2) generating new and important data related to mechanisms of how diabetes attenuates neuronal and endothelial repair processes by using combinations of animal models of diabetes or stroke to recapitulate the clinical condition, and 3) identification of iron as a new DAMP and show that iron chelation and/or downstream TLR4 inhibition are promising therapeutic targets in stroke treatment/recovery. This project will have a significant positive impact on stroke research and human health because it will 1) identify neurovascular protection and restoration strategies to improve stroke outcomes, 2) advance our knowledge of the role of the cerebral vasculature in stroke repair, and 3) provide specific information on stroke recovery in diabetes which occurs in more than 30% of the 800,000 annual stroke victims.

Public Health Relevance

More than 7% of the US population has diabetes. Diabetic patients suffer from stroke injury to a greater extent, especially bleeding into the brain, and als experience poor recovery after stroke. However, we do not know the impact of bleeding on stroke recovery. This project will determine the mechanisms how bleeding affect the repair of the brain after stroke in diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS083559-05
Application #
9412924
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Koenig, James I
Project Start
2014-02-01
Project End
2020-01-31
Budget Start
2018-02-01
Budget End
2020-01-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Augusta University
Department
Physiology
Type
Schools of Medicine
DUNS #
City
Augusta
State
GA
Country
United States
Zip Code
30912
Jackson, LaDonya; Eldahshan, Wael; Fagan, Susan C et al. (2018) Within the Brain: The Renin Angiotensin System. Int J Mol Sci 19:
Coucha, Maha; Abdelsaid, Mohammed; Ward, Rebecca et al. (2018) Impact of Metabolic Diseases on Cerebral Circulation: Structural and Functional Consequences. Compr Physiol 8:773-799
Abdul, Yasir; Abdelsaid, Mohammed; Li, Weiguo et al. (2018) Inhibition of Toll-Like Receptor-4 (TLR-4) Improves Neurobehavioral Outcomes After Acute Ischemic Stroke in Diabetic Rats: Possible Role of Vascular Endothelial TLR-4. Mol Neurobiol :
Hafez, Sherif; Abdelsaid, Mohammed; Fagan, Susan C et al. (2018) Peroxynitrite-Induced Tyrosine Nitration Contributes to Matrix Metalloprotease-3 Activation: Relevance to Hyperglycemic Ischemic Brain Injury and Tissue Plasminogen Activator. Neurochem Res 43:259-266
Ahmed, Heba A; Ishrat, Tauheed; Pillai, Bindu et al. (2018) Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study. Behav Brain Res 346:29-40
Fouda, Abdelrahman Y; Alhusban, Ahmed; Ishrat, Tauheed et al. (2017) Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke. Mol Neurobiol 54:661-670
Abdelsaid, Mohammed; Coucha, Maha; Hafez, Sherif et al. (2017) Enhanced VEGF signalling mediates cerebral neovascularisation via downregulation of guidance protein ROBO4 in a rat model of diabetes. Diabetologia 60:740-750
Fouda, Abdelrahman Y; Newsome, Andrea S; Spellicy, Samantha et al. (2017) Minocycline in Acute Cerebral Hemorrhage: An Early Phase Randomized Trial. Stroke 48:2885-2887
Alhusban, Ahmed; Kozak, Anna; Pillai, Bindu et al. (2017) Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension. PLoS One 12:e0178867
Fouda, Abdelrahman Y; Pillai, Bindu; Dhandapani, Krishnan M et al. (2017) Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injury. Eur J Pharmacol 799:128-134

Showing the most recent 10 out of 50 publications